View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
July 16, 2019

North America’s pharma industry sees a drop of 10.3% in deal activity in Q2 2019

North America’s pharma industry saw a drop of 10.3% in overall deal activity during Q2 2019, when compared to the four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 234 deals worth $23.62bn were announced for the region during Q2 2019, against the last four-quarter average of 261 deals.

Of all the deal types, venture financing saw most activity in Q2 2019 with 161, representing a 68.8% share for the region.

In second place was M&A with 58 deals, followed by private equity deals with 15 transactions, respectively capturing a 24.8% and 6.4% share of the overall deal activity for the quarter.

In terms of value of deals, M&A was the leading category in North America’s pharma industry with $19.55bn, while venture financing and private equity deals totalled $2.8bn and $1.27bn, respectively.

North America pharma industry deals in Q2 2019: Top deals

The top five pharma deals accounted for 73.6% of the overall value during Q2 2019.

The combined value of the top five pharma deals stood at $17.38bn, against the overall value of $23.62bn recorded for the quarter. The top announced pharma deal tracked by GlobalData in Q2 2019 was Pfizer’s $11.4bn acquisition of Array BioPharma.

In second place was the $2.2bn acquisition of Peloton Therapeutics by Merck &Inc and in third place was Novartis’ $1.58bn acquisition of IFM Tre.

The $1.2bn acquisition of Paragon Bioservices by Catalent and Vertex Pharmaceuticals’ acquisition of Exonics Therapeutics for $1bn held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU